<DOC>
	<DOCNO>NCT01142284</DOCNO>
	<brief_summary>Based upon evidence efficacy safety cilostazol probucol administration independent randomize controlled trial PAD CAD , present trial seek investigate effect concomitant administration cilostazol probucol FMD compare drug individually , well evaluate biomarker measure safety index context .</brief_summary>
	<brief_title>Evaluation Concomitant Administration Cilostazol Probucol Biomarkers , Endothelial Function Safety</brief_title>
	<detailed_description>Primary : 1 . To evaluate effect concomitant administration cilostazol probucol 12-week change FMD baseline compare , individual drug alone . 2 . To assess safety concomitant administration cilostazol probucol peripheral artery disease ( PAD ) subject complicate coronary artery disease ( CAD ) determine physical examination , vital sign , adverse event ( AEs ) , laboratory test , ECGs . Secondary : 1 . To evaluate effect cilostazol probucol administer concomitantly individual drug , compare control , change FMD baseline Weeks 6 12 . 2 . To evaluate effect cilostazol probucol administer concomitantly individual drug , compare control , change metabolic , inflammatory , oxidative , platelet biomarkers baseline Weeks 6 12 . 3 . To evaluate effect cilostazol probucol administer concomitantly individual drug , compare control , time course ( 12-week treatment period ) change FMD biomarkers level . 4 . To assess effect drug withdrawal endpoint follow-up ( Week 12 Week 16 ) . 5 . To explore relationship change FMD change biomarker level Week 12 .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>1 . Age ≥ 40 &lt; 80 year Screening . 2 . The subject diagnosis PAD 3 . The subject diagnosis CAD 4 . Stable background medical therapy past 3 month 5 . Taking 100mg/day aspirin 75mg/day clopidogrel past 3 month 6 . Hyperlipidemia define LDL cholesterol concentration &gt; 70 mg/dL 7 . The subject willing participate study document write informed consent 1 . New diagnosis PAD within 3 month . 2 . Currently take cilostazol take cilostazol 3 . Currently take probucol take probucol within last 3 month 4 . Critical limb ischemia ( CLI ) 5 . Congestive heart failure 6 . Transient ischemic attack ( TIA ) 7 . Endovascular peripheral coronary revascularization procedure within 3 month 8 . Coronary artery bypass graft ( CABG ) major cardiovascular surgical procedure within 6 month 9 . Major surgical procedure within 3 month 10 . Uncontrolled hypertension 11 . Type 1 diabetes mellitus poorly control type 2 diabetes mellitus 12 . Diabetic complication severe peripheral neuropathy active retinopathy . 13 . Inflammatory bowel disease . 14 . Unstable angina 15 . QT prolongation 16 . Severe life threaten ventricular arrhythmia 17 . History syncope 18 . Serum creatinine &gt; 2.5 mg/dL , Creatinine Clearance ≤25ml/min renal failure require dialysis . 19 . History evidence hematological clotting disorder . 20 . Hematocrit ≤ 28 % ≥ 55 % . 21 . AST ALT &gt; 3 time upper limit normal ( ULN ) . 22 . Any form chronic anticoagulation . 23 . Coagulopathies define INR &gt; 1.5 24 . History malignant disease within 5 year . 25 . Acute chronic hepatitis . 26 . Hemophilia know increase risk hemorrhage . 27 . Other clinically significant disorder result remain life expectancy le one year . 28 . Current alcohol drug abuse . 29 . If female , subject pregnant breastfeeding must nonchildbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Biomarker</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Flow Mediated Dilation</keyword>
	<keyword>Cilostazol</keyword>
	<keyword>Probucol</keyword>
</DOC>